<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04648137</url>
  </required_header>
  <id_info>
    <org_study_id>2020-02147; me20ChristCrain4</org_study_id>
    <nct_id>NCT04648137</nct_id>
  </id_info>
  <brief_title>Circulating Oxytocin Changes in Response to the Oxytocin System Stimulator MDMA in Patients With Diabetes Insipidus and Healthy Controls</brief_title>
  <acronym>OxyMA</acronym>
  <official_title>Circulating Oxytocin Changes in Response to the Oxytocin System Stimulator MDMA in Patients With Diabetes Insipidus and Healthy Controls</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Basel, Switzerland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Basel, Switzerland</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to evaluate oxytocin levels in response to MDMA administration as compared to&#xD;
      placebo in patients with diabetes insipidus and healthy volunteers.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Disruption of the hypothalamic-pituitary axis due to congenital abnormalities, tumors or head&#xD;
      trauma may cause anterior and/or posterior pituitary deficiency also known as partial or&#xD;
      panhypopituitarism. Patients with hypopituitarism, especially those with panhypopituitarism&#xD;
      (i.e., anterior and posterior insufficiency) often report residual symptoms and lower quality&#xD;
      of life despite adequate substitution treatment of deficient pituitary hormones. A recent&#xD;
      study identified a potential oxytocin deficient state in men with combined anterior and&#xD;
      posterior deficiency. Due to the close proximity of vasopressin and oxytocin, disruption of&#xD;
      the vasopressin system leading to diabetes insipidus could as well disturb the oxytocin&#xD;
      system leading to low oxytocin levels. It is therefore possible that the increased&#xD;
      psychopathology and reduced quality of life as observed in patients with central diabetes&#xD;
      insipidus is caused by an oxytocin deficiency. Several studies documented marked acute&#xD;
      increases in circulating oxytocin levels in response to 3,4-methylenedioxymethamphetamine&#xD;
      (MDMA) administration as compared to placebo in healthy volunteers.&#xD;
&#xD;
      MDMA could therefore be useful as a provocation test to detect an oxytocin deficiency in&#xD;
      patients with central diabetes insipidus. This study is to investigate if oxytocin&#xD;
      provocation following a single dose administration of MDMA is reduced in patients with&#xD;
      central diabetes insipidus as compared to healthy volunteers.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 5, 2021</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Randomized, double-blind, placebo-controlled, cross-over (MDMA versus placebo, within subject comparison) study in patients with central diabetes insipidus versus healthy controls (between-subject comparison). Participants will be randomized to receive either first placebo or first MDMA, respectively.</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>area under the concentration time curve in oxytocin level</measure>
    <time_frame>from baseline oxytocin measurement (before intake) to 6 hours after administration of MDMA</time_frame>
    <description>area under the concentration time curve in oxytocin level from baseline oxytocin measurement (before intake) to 6 hours after a single administration of MDMA (100mg) as compared to placebo in the same subjects between patients with central diabetes insipidus and healthy volunteers.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Peak change in oxytocin (OT) plasma level</measure>
    <time_frame>from baseline oxytocin measurement (before intake) to 6 hours after administration of MDMA</time_frame>
    <description>Peak change in OT plasma level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time course of plasma OT levels</measure>
    <time_frame>from baseline oxytocin measurement (before intake) to 6 hours after administration of MDMA</time_frame>
    <description>Time course of plasma OT levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time course of plasma MDMA concentration</measure>
    <time_frame>from baseline oxytocin measurement (before intake) to 6 hours after administration of MDMA</time_frame>
    <description>Time course of plasma MDMA concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time course of cortisol levels</measure>
    <time_frame>from baseline oxytocin measurement (before intake) to 6 hours after administration of MDMA</time_frame>
    <description>Time course of cortisol levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time course of prolactin levels</measure>
    <time_frame>from baseline oxytocin measurement (before intake) to 6 hours after administration of MDMA</time_frame>
    <description>Time course of prolactin levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time course of copeptin levels</measure>
    <time_frame>from baseline oxytocin measurement (before intake) to 6 hours after administration of MDMA</time_frame>
    <description>Time course of copeptin levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time course of adrenocorticotropic hormone (ACTH) levels</measure>
    <time_frame>from baseline oxytocin measurement (before intake) to 6 hours after administration of MDMA</time_frame>
    <description>Time course of ACTH levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjective/emotional effects</measure>
    <time_frame>from baseline oxytocin measurement (before intake) to 6 hours after administration of MDMA</time_frame>
    <description>Subjective/emotional effects assessed on a 10-point visual analog scale (e.g., feelings of anxiety, pleasure, fear, 0 = better outcome,10 = worst outcome)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recognition of negative emotions in the face emotion recognition task (FERT)</measure>
    <time_frame>from baseline oxytocin measurement (before intake) to 6 hours after administration of MDMA</time_frame>
    <description>Recognition of negative emotions in the face emotion recognition task (FERT)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Empathy in the multifaceted empathy task (MET)</measure>
    <time_frame>from baseline oxytocin measurement (before intake) to 6 hours after administration of MDMA</time_frame>
    <description>Empathy in the multifaceted empathy task (MET)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anxiety level with the State-Trait Anxiety Inventory (STAI)</measure>
    <time_frame>from baseline oxytocin measurement (before intake) to 6 hours after administration of MDMA</time_frame>
    <description>Anxiety level with the State-Trait Anxiety Inventory (STAI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Level of Alexithymia using the Toronto-Alexithymia-Scale 20 (TAS-20)</measure>
    <time_frame>from baseline oxytocin measurement (before intake) to 6 hours after administration of MDMA</time_frame>
    <description>Level of Alexithymia using the Toronto-Alexithymia-Scale 20 (TAS-20); total scores can range from 20-100, with higher scores indicating greater impairment/challenges</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Level of depression using the Beck-Depressions-Inventory II (BDI-II)</measure>
    <time_frame>from baseline oxytocin measurement (before intake) to 6 hours after administration of MDMA</time_frame>
    <description>Level of depression using the Beck-Depressions-Inventory II (BDI-II); 21-question multiple-choice self-report inventory. Higher total scores indicate more severe depressive symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Level of general physical &amp; mental health using the short form health survey (SF-36)</measure>
    <time_frame>from baseline oxytocin measurement (before intake) to 6 hours after administration of MDMA</time_frame>
    <description>Level of general physical &amp; mental health using the short form health survey (SF-36); 36-item, patient-reported survey of patient health; the higher the score, the more favourable the health state.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Diabetes Insipidus</condition>
  <arm_group>
    <arm_group_label>Patients with central diabetes insipidus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy volunteers</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>study intervention: 3,4-methylenedioxymethamphetamine (MDMA, ecstasy)</intervention_name>
    <description>single administration of MDMA (100mg): 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) will be prepared as gelatin capsules with mannitol as the filler. MDMA will be administered in a single absolute dose of 100 mg corresponding to a medium high dose of (mean ± SD) 1.3 ± 0.3 mg/kg body weight.</description>
    <arm_group_label>Healthy volunteers</arm_group_label>
    <arm_group_label>Patients with central diabetes insipidus</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Control intervention: Placebo</intervention_name>
    <description>Identical placebo (only mannitol) capsules</description>
    <arm_group_label>Healthy volunteers</arm_group_label>
    <arm_group_label>Patients with central diabetes insipidus</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria diabetes insipidus:&#xD;
&#xD;
          -  Confirmed diagnosis of central diabetes insipidus&#xD;
&#xD;
        Inclusion criteria healthy volunteers:&#xD;
&#xD;
          -  Matched for age, sex, BMI and estrogen replacement/menopause/hormonal contraceptives&#xD;
             to patients with central diabetes insipidus&#xD;
&#xD;
          -  No medication, except hormonal contraception-&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Familial central diabetes insipidus&#xD;
&#xD;
          -  Participation in a trial with investigational drugs within 30 days&#xD;
&#xD;
          -  Illicit substance use (with the exception of cannabis) more than 10 times in lifetime&#xD;
             or any time within the previous two months&#xD;
&#xD;
          -  Consumption of alcoholic beverages &gt;15 drinks/week&#xD;
&#xD;
          -  Tobacco smoking &gt;10 cigarettes/day&#xD;
&#xD;
          -  Cardiovascular disease (coronary artery disease, heart failure, left ventricular&#xD;
             ejection fraction ( LVEF) &lt;40%, stroke in the last 3 months, atrial&#xD;
             fibrillation/flatter, Wolff-Parkinson-White syndrome (WPW)-Syndrome)&#xD;
&#xD;
          -  Uncontrolled arterial hypertension (&gt;140/90 mmHg) or hypotension (syst blood pressure&#xD;
             &lt;85mmHg)&#xD;
&#xD;
          -  Current or previous major psychiatric disorder (e.g., major depression, schizophrenia&#xD;
             spectrum disorder)&#xD;
&#xD;
          -  Psychotic disorder in first-degree relatives&#xD;
&#xD;
          -  Regular intake of selective serotonin reuptake inhibitor (SSRI), monoamine oxidase&#xD;
             (MAO)-Inhibitors&#xD;
&#xD;
          -  Pregnancy and breastfeeding&#xD;
&#xD;
          -  Diagnosed chronic kidney disease (CKD) &gt; grade III (GRF &lt; 30ml/min)&#xD;
&#xD;
          -  Diagnosed liver cirrhosis or alanine aminotransferase (ALAT) or aspartate&#xD;
             aminotransferase (ASAT) levels 2.5 times above the normal range&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mirjam Christ-Crain, Prof. Dr. med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Endocrinology, Diabetes and Metabolism, University Hospital Basel</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mirjam Christ-Crain, Prof. Dr. med.</last_name>
    <phone>+41 61 265 25 25</phone>
    <email>Mirjam.Christ-Crain@usb.ch</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Cihan Atila, Dr.</last_name>
    <email>cihan.atila@usb.ch</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital Basel, Endocrinology, Diabetes and Metabolism</name>
      <address>
        <city>Basel</city>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mirjam Christ-Crain, Prof. Dr. med.</last_name>
      <phone>+41 61 265 25 25</phone>
      <email>Mirjam.Christ-Crain@usb.ch</email>
    </contact>
    <contact_backup>
      <last_name>Cihan Atila, Dr.</last_name>
      <email>cihan.atila@usb.ch</email>
    </contact_backup>
    <investigator>
      <last_name>Mirjam Christ-Crain, Prof. Dr. med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Cihan Atila, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Matthias Liechti, Prof. Dr. med.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bettina Winzeler, Dr. med.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>November 23, 2020</study_first_submitted>
  <study_first_submitted_qc>November 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 1, 2020</study_first_posted>
  <last_update_submitted>February 8, 2021</last_update_submitted>
  <last_update_submitted_qc>February 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>central diabetes insipidus</keyword>
  <keyword>oxytocin levels</keyword>
  <keyword>3,4-methylenedioxymethamphetamine (MDMA)</keyword>
  <keyword>hypothalamic-pituitary axis</keyword>
  <keyword>hypopituitarism</keyword>
  <keyword>vasopressin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Insipidus</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>N-Methyl-3,4-methylenedioxyamphetamine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

